ATE535535T1 - Methoden für die diagnose von demenz und anderen neurologischen erkrankungen - Google Patents

Methoden für die diagnose von demenz und anderen neurologischen erkrankungen

Info

Publication number
ATE535535T1
ATE535535T1 AT07710657T AT07710657T ATE535535T1 AT E535535 T1 ATE535535 T1 AT E535535T1 AT 07710657 T AT07710657 T AT 07710657T AT 07710657 T AT07710657 T AT 07710657T AT E535535 T1 ATE535535 T1 AT E535535T1
Authority
AT
Austria
Prior art keywords
patient
alzheimer
disease dementia
accurate mass
methods
Prior art date
Application number
AT07710657T
Other languages
English (en)
Inventor
Lisa Cook
Dayan Goodenowe
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Application granted granted Critical
Publication of ATE535535T1 publication Critical patent/ATE535535T1/de

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin
    • C07F9/106Adducts, complexes, salts of phosphatides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00Details not covered by any other group of this subclass
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/62Detectors specially adapted therefor
    • G01N30/72Mass spectrometers
    • G01N30/7233Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/16Phosphorus containing
    • Y10T436/163333Organic [e.g., chemical warfare agents, insecticides, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Primary Health Care (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07710657T 2006-02-28 2007-02-28 Methoden für die diagnose von demenz und anderen neurologischen erkrankungen ATE535535T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77729006P 2006-02-28 2006-02-28
US80477906P 2006-06-14 2006-06-14
US88888307P 2007-02-08 2007-02-08
PCT/CA2007/000313 WO2007098585A1 (en) 2006-02-28 2007-02-28 Methods for the diagnosis of dementia and other neurological disorders

Publications (1)

Publication Number Publication Date
ATE535535T1 true ATE535535T1 (de) 2011-12-15

Family

ID=38458611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07710657T ATE535535T1 (de) 2006-02-28 2007-02-28 Methoden für die diagnose von demenz und anderen neurologischen erkrankungen

Country Status (11)

Country Link
US (2) US8304246B2 (de)
EP (3) EP2851369A3 (de)
JP (3) JP5496513B2 (de)
KR (1) KR20080104350A (de)
AT (1) ATE535535T1 (de)
AU (1) AU2007219666A1 (de)
CA (2) CA2689848A1 (de)
HK (1) HK1208467A1 (de)
IL (1) IL193426A0 (de)
NZ (1) NZ570413A (de)
WO (1) WO2007098585A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117527B1 (de) 2007-02-08 2020-06-17 Med-Life Discoveries LP Verbindungen zur verwendung bei der behandlung von altersdemenz vom alzheimer-typ
CA2680748C (en) * 2007-04-13 2012-08-28 Phenomenome Discoveries Inc. Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
US20140365895A1 (en) 2008-05-13 2014-12-11 Apple Inc. Device and method for generating user interfaces from a template
US9121844B1 (en) * 2008-09-09 2015-09-01 Sociedad Europea de Analisis Diferencial de Movilidad Method to analyze and classify persons and organisms based on odor patterns from released vapors
TWI475989B (zh) 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物,含彼之醫藥組成物以及治療老化疾病的方法
EP3124980A1 (de) 2009-10-01 2017-02-01 Phenomenome Discoveries Inc. Mass-spectrophotometrische methode zur diagnose pancreatischem krebs
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
EP2596132A4 (de) 2010-07-23 2013-12-18 Harvard College Verfahren zur erkennung von anzeichen für krankheiten oder leiden in körperflüssigkeiten
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
WO2012090625A1 (ja) * 2010-12-28 2012-07-05 医療法人社団ブックス 認知症を血液サンプルで判定するための検査方法
AU2012321071B2 (en) * 2011-11-17 2015-02-26 Med-Life Discoveries Lp Methods for the synthesis of 13C labeled plasmalogen
WO2013119651A1 (en) * 2012-02-08 2013-08-15 Nestec Sa Methods for diagnosing cognitive impairment
US20150031572A1 (en) * 2012-02-15 2015-01-29 Basf Se Means and methods for assessing neuronal toxicity
CN104246781B (zh) * 2012-03-29 2019-06-14 皇家飞利浦有限公司 用于改进神经科医师的关于阿尔茨海默氏病的工作流程的系统与方法
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ, 疾患または状態を検出する方法
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
DE202014004560U1 (de) * 2013-06-08 2014-09-12 Apple Inc. Vorrichtung und grafische Benutzerschnittstelle zum Synchronisieren zweier oder mehrerer Anzeigen
CA2926592A1 (en) * 2013-11-14 2015-05-21 Nestec S.A. Lipid biomarkers of healthy ageing
WO2015138879A1 (en) * 2014-03-13 2015-09-17 Massachusetts Institute Of Technology Compositions containing pufa, uridine and choline and methods of use thereof
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
US10006925B2 (en) 2016-05-30 2018-06-26 Universal Diagnostics, S. L. Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
GB201611596D0 (en) * 2016-07-04 2016-08-17 British American Tobacco Investments Ltd Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories
US20200241011A1 (en) * 2017-02-24 2020-07-30 Mattias ARNOLD Compositions and methods related to sex- specific metabolic drivers in alzheimers disease
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US20190385711A1 (en) 2018-06-19 2019-12-19 Ellipsis Health, Inc. Systems and methods for mental health assessment
JP7608171B2 (ja) 2018-06-19 2025-01-06 エリプシス・ヘルス・インコーポレイテッド 精神的健康評価のためのシステム及び方法
JP7389421B2 (ja) * 2018-07-13 2023-11-30 Pst株式会社 精神・神経系疾患を推定する装置
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2022263927A2 (en) * 2021-06-17 2022-12-22 Phoska Biopharma Pte. Ltd. Plasmalogen derivatives and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2001286059A1 (en) * 2000-09-08 2002-03-22 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
WO2002082075A2 (de) 2001-04-06 2002-10-17 Biovision Ag Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
CA2446666A1 (en) * 2001-05-09 2002-11-14 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
CA2745998C (en) * 2002-08-23 2013-11-26 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) * 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) * 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
JP4176749B2 (ja) * 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Also Published As

Publication number Publication date
EP2322531A2 (de) 2011-05-18
JP2009528517A (ja) 2009-08-06
JP2012255793A (ja) 2012-12-27
EP1922325A4 (de) 2009-05-27
JP5496513B2 (ja) 2014-05-21
EP1922325A1 (de) 2008-05-21
KR20080104350A (ko) 2008-12-02
WO2007098585A1 (en) 2007-09-07
AU2007219666A1 (en) 2007-09-07
JP2014197018A (ja) 2014-10-16
IL193426A0 (en) 2009-05-04
EP2322531A3 (de) 2011-09-07
EP2851369A3 (de) 2015-06-17
NZ570413A (en) 2011-07-29
CA2640748A1 (en) 2007-09-07
HK1208467A1 (en) 2016-03-04
US20130110408A1 (en) 2013-05-02
CA2689848A1 (en) 2007-09-07
CA2640748C (en) 2010-04-20
EP2851369A2 (de) 2015-03-25
EP1922325B1 (de) 2011-11-30
HK1113160A1 (en) 2008-09-26
US8304246B2 (en) 2012-11-06
US20100003761A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
BRPI0516674A (pt) método de análise de mal de alzheimer e reagente de diagnóstico
ATE467834T1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2021067850A3 (en) METHODS OF DETECTING circRNA
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
EP2672266A3 (de) Verfahren zum Screening einer Lungen-Transplantation Kandidat für ein erhöhtes Risiko einer Abstoßung
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
DK1664793T3 (da) Neurotoksisk aminosyre eller neurotoksisk derivat deraf forbundet med neurologiske lidelser
EP1600513A4 (de) Verfahren zur untersuchung einer zelle
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
EP2338988A4 (de) Beurteilungs-/screeningverfahren für erkrankungen in zusammenhang mit d-aminosäure mittels dao1-/-maus
Klunk et al. Small molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
ATE459877T1 (de) Diagnostikum für die frühe phase von morbus alzheimer
Singhal et al. Salivary biomarkers for neurodegenerative disorder for biomedical sensing
Klunk et al. Quantitative in vitro NMR analysis of Alzheimer's, non-Alzheimer's demented and control brain
ATA19972000A (de) Pibf für die diagnose von tumoren
ATE509270T1 (de) Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung
Tuokko et al. Mild cognitive impairment
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen